IMC-002

BIOLOGICAL3 trials

Sponsors

ImmuneOncia Therapeutics Inc., ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Conditions

Advanced CancerLymphomaNeuromyelitis Optica Spectrum Disorder (NMOSD)Solid Tumor

Phase 1

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

CompletedNCT04306224

ImmuneOncia Therapeutics Inc.Lymphoma, Solid Tumor

Start: 2020-06-05End: 2022-10-07Updated: 2024-04-12

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

RecruitingNCT05276310

ImmuneOncia Therapeutics Inc.Advanced Cancer

Start: 2022-06-02End: 2029-08-30Target: 62Updated: 2026-04-24

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Not yet recruitingNCT06557174

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Neuromyelitis Optica Spectrum Disorder (NMOSD)

Start: 2024-10-10End: 2026-07-10Target: 116Updated: 2024-08-16

Related Papers

Phase 1b dose-expansion study of IMC-002, a anti-CD47 monoclonal antibody, in patients with advanced triple negative breast cancer (TNBC).

Journal of Clinical Oncology2026-05-27

Abstract 4355: Cryo EM-based structural characterization of IMC-002, a next-generation anti-CD47 antibody with a unique binding site and biomarker candidates, supporting evidence of enhanced safety and efficacy

Cancer Research2026-04-03

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.

2025-11-04

Phase 1b dose extension study of a next-generation anti-CD47 monoclonal antibody IMC-002 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2025-05-28

Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations